These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 19121150)

  • 1. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
    Olliaro P; Darley S; Laxminarayan R; Sundar S
    Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug combinations for visceral leishmaniasis.
    Olliaro PL
    Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.
    Meheus F; Boelaert M; Baltussen R; Sundar S
    Trop Med Int Health; 2006 Nov; 11(11):1715-24. PubMed ID: 17054752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
    Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
    Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
    N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
    Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
    Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
    Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Visceral leishmaniases].
    Rosenthal E; Marty P
    Rev Prat; 2004 Dec; 54(20):2211-6. PubMed ID: 15736529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
    Meheus F; Balasegaram M; Olliaro P; Sundar S; Rijal S; Faiz MA; Boelaert M
    PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20838649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
    Murray HW
    Expert Rev Anti Infect Ther; 2004 Apr; 2(2):279-92. PubMed ID: 15482193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
    Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
    Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.